OPK240719P1000
- 0.03
- 0.000.00%
Opko Health Newsroom
Piper Sandler Adjusts Price Target on OPKO Health to $3 From $5, Maintains Overweight Rating
OPKO Health Analyst Ratings
Opko Health (OPK) Gets a Buy From Piper Sandler
Analysts' Top Healthcare Picks: Opko Health (OPK), Pharming Group (PHAR)
OPKO Health Analyst Ratings
HC Wainwright & Co. Reiterates Buy on OPKO Health, Maintains $3 Price Target
Piper Sandler Sticks to Its Buy Rating for Opko Health (OPK)
Opko Health Poised for Growth: Buy Rating Affirmed Amid Topline Expansion and Strategic Transactions
Opko Health Buy Rating Backed by Strategic Asset Sale and Promising Oral Drug Candidate
OPKO Health Analyst Ratings
Critical Insights From OPKO Health Analyst Ratings: What You Need To Know
OPKO Health Analyst Ratings
Buy Rating Affirmed for Opko Health Amid Strategic Divestiture and Operational Improvement Prospects
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Opko Health (OPK) and Leafly Holdings, Inc. (LFLY)
Barrington Cuts Price Target on OPKO Health to $1.50 From $2, Maintains Outperform Rating
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR), Beam Therapeutics (BEAM) and Opko Health (OPK)
Optimistic Future Prospects and Financial Performance Bolster Buy Rating for Opko Health
Opko Health Maintains Buy Rating Amid Promising Q3 Results and Global Growth Hormone Expansion
Piper Sandler Sticks to Their Buy Rating for Opko Health (OPK)
Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Sagimet Biosciences, Inc. Class A (SGMT)